Drug Information



Brand Name:Taxol Trade Name:paclitaxel
FDA Approved For:TAXOL is indicated, after failure of first-line or subsequent chemotherapy for the treatment of metastatic carcinoma of the ovary. TAXOL is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. TAXOL is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma. Pediatric Use:The safety and effectiveness of TAXOL in pediatric patients have not been established.
Carcinogen:The carcinogenIc potential of TAXOL has not been studied.Mutagen:Paclitaxel has been shown to be clastogenic in vitro ( chromosome aberrations in human lymphocytes) and in vivo ( micronucleus test in mice). Paclitaxel was not mutagenic in the Ames test or the CHO/ HGPRT gene mutation assay.
Manufacturer and/or Distributor:Bristol-Myers Squibb

Adverse Reactions:

For a complete list of adverse reactions please click on the link "More Information" for this drug.)

More Information